logo
  Join        Login             Stock Quote

Sucampo (SCMP) Receives Milestone Payment From Abbott (ABT) For Chronic Constipation Therapy In Japan

 December 11, 2012 07:21 AM
 


(By Balaseshan) Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) said its unit has received a milestone payment of $15 million from Abbott Laboratories (NYSE: ABT) on first sale of chronic constipation treating prescription medication Amitiza (lubiprostone) in Japan.

Sucampo AG has received a $15 million milestone payment from Abbott Japan Co. Ltd., pursuant to the existing license, commercialization, and supply agreement between Sucampo Pharma Ltd. (SPL), SPI's subsidiary, and Abbott.

The milestone payment was triggered by the first sale of Amitiza (lubiprostone) capsule 24 µg in Japan. Amitiza is available through Abbott in Japan as a prescription medication for chronic constipation not caused by organic diseases, and was launched to primary care and specialist physicians on November 21, 2012.

[Related -Can Abbvie Inc (NYSE:ABBV) Trump Gilead Sciences, Inc.'S (NASDAQ:GILD) HCV Lead?]

Amitiza is the world's first chloride channel activator approved for therapeutic use, and has a unique mechanism of action to restore mucosal barrier function. With more than six million prescriptions worldwide, it is the first and currently the only prescription medicine available in Japan for chronic constipation.

"The availability and first sale of Amitiza in Japan is another step forward in the company's objective of bringing medicines with novel mechanisms of action to patients globally with unmet medical needs," said Sucampo's Chairman, Chief Executive Officer, and Chief Scientific Officer Ryuji Ueno.

[Related -Abbvie Inc (NYSE:ABBV): Ready To Shift Gears In 2014?]

In 2009, SPL and Abbott entered into a license, commercialization and supply agreement for Amitiza in Japan.

Outside Japan, Amitiza is approved in the United States for the treatment of chronic idiopathic constipation (CIC) in adults (24 mcg twice daily) and irritable bowel syndrome with constipation (IBS-C) in women 18 years of age and older (8 mcg twice daily). Amitiza is also approved for chronic idiopathic constipation in Switzerland and the United Kingdom.

SCMP closed Monday's regular session up 0.43% at $4.66, while ABT ended down 0.31% at $65.33.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageIntel Corporation (INTC) Q1 Earnings Preview: A Business in Transition

Intel Corporation (NASDAQ:INTC) plans to post its first quarter earnings results promptly after the market read on...

article imageFord Motor Company (F): A long Road to Deutsche Bank’s $19 Target

Ford Motor Company (NYSE:F) is going the right way on a one way street where most everybody else is driving read on...

article imageCitigroup Inc (C) Q1 Earnings Preview: Too Many Parts Heading South

Citigroup Inc (NYSE:C) will issue its first quarter results via press release at approximately 8 a.m. (ET) read on...

article imageFacebook Inc (FB): You Might Not Like It Today, But You’ll Like It Tomorrow

Do you honestly want to invest in stocks right now? It sure looks like the bull market is at least on read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Optimism Moving Back Into The Equation
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.